Biote (BTMD) Q4 2025 earnings review
Core Revenues Plunge as 'Transition Year' Bleeds into 2026
Biote capped off a difficult 2025 with an accelerating 13.0% collapse in Q4 core procedure revenue, dragging total revenue down 6.9% YoY. A strategic misstep with their May 2025 sales reorganization continues to relentlessly pressure the top line. Adding insult to injury, their highly-touted vertical integration at Asteria Health suffered a product recall, triggering a $1.3M inventory charge and crushing gross margins down to 68.0%. Management promises a return to procedure growth in H2 2026, but the cost of this turnaround is staggering: 2026 Adjusted EBITDA is guided to plummet to 'Above $38 million' (down ~29% YoY) due to massive, necessary commercial reinvestments.
🐂 Bull Case
The dietary supplements segment remains a reliable growth driver, accelerating to 16.0% YoY growth in Q4 ($11.7 million) and partially buffering the core procedure declines.
Operating income surged 146.8% YoY to $6.8M in Q4, demonstrating that management can extract short-term profitability through strict headcount and legal expense reductions.
🐻 Bear Case
The lifeblood of the company—procedure revenue—is in an accelerating freefall, moving from -3.6% YoY in Q1 to -13.0% YoY in Q4. Reversing this trend is not expected until the second half of 2026.
The promised turnaround requires massive sales force investments. FY26 Adjusted EBITDA is guided to 'Above $38 million', implying a massive ~29% deceleration from FY25's $53.5 million.
⚖️ Verdict: 🔴
Bearish. The 'transition' is taking much longer and costing far more than anticipated. Core volumes are accelerating downward, product quality issues emerged at their internal facility, and margins are set to compress significantly in 2026.
Key Themes
Asteria Health Recall Breaks Margin Thesis
A major red flag emerged as Biote recorded a $1.3 million inventory impairment charge due to a voluntary recall of bioidentical hormone pellets shipped by its in-house Asteria Health facility between May 2025 and January 2026. This completely reversed the gross margin expansion narrative, compressing Q4 gross margins to 68.0% from 71.8% a year ago. It raises critical questions about quality control and potential liability within their vertically integrated supply chain.
Procedure Revenue Freefall Accelerates
The company's core economic engine is failing. Procedure revenue declines are violently accelerating: -3.6% in Q1, -8.4% in Q2, -10.4% in Q3, and now -13.0% in Q4. The disruption from May's commercial reorganization has proven to be much deeper and more persistent than management initially communicated, resulting in high clinic attrition and a dried-up pipeline of new practitioners.
The High Cost of the 2026 Rebuild
Management explicitly warned of a 'meaningful step-up in operating expenses in 2026' to heavily invest in sales and technology capabilities. After starving the business of OPEX to prop up EBITDA in late 2025, they must now pay the piper to re-accelerate growth. This dynamic transforms Biote from a high-margin compounder into a 'show-me' turnaround story with heavy near-term margin compression.
Dietary Supplements Remain a Bright Spot
Driven by a successful expansion onto Amazon and robust e-commerce execution, dietary supplements revenue grew a highly stable 16.0% YoY in Q4 to $11.7 million, bringing full-year growth to 19.1%. This segment provides critical cash flow while the core procedure business is overhauled.
Other KPIs
Accelerating positively. Despite plunging revenues and a severe gross margin hit, operating income soared 146.8% YoY. This was entirely engineered through a massive cut in Selling, General and Administrative expenses ($24.7M vs $33.0M a year prior), largely reflecting reduced legal costs and temporary headcount vacancies from the commercial reorganization.
Decelerating. Operating cash flow dropped from $45.2 million in FY24 to $35.2 million in FY25. Net cash decreased dramatically by $15.2M over the year to $24.1 million, largely due to $37.6 million deployed toward share repurchase liabilities and settling founder exit agreements.
Guidance
Decelerating violently. This implies a massive ~29% drop from the $53.5 million achieved in FY25. The collapse in projected profitability lays bare the intense costs required to rebuild the sales organization and reignite the stagnant procedure segment.
Stable to slightly declining. Compared to the actual $192.2 million achieved in FY25, this guidance assumes flat performance as H1 procedure declines offset H2 procedural recovery and ongoing supplement growth.
Reversing trajectory. Management is effectively writing off the first half of 2026, predicting ongoing contraction before the newly expanded salesforce fully ramps up and yields positive net new clinic additions in the second half of the year.
Decelerating. Growth is expected to cool significantly from the 19.1% surge seen in FY25, primarily as the company begins lapping much tougher year-over-year comparables from its successful Amazon launch.
Key Questions
Asteria Health Recall Impact
Regarding the $1.3M inventory charge and recall of Asteria pellets shipped between May 2025 and Jan 2026: How many clinics and patients were impacted, and are you seeing elevated clinic attrition explicitly tied to this quality control failure?
EBITDA Compression Trajectory
Your FY26 Adjusted EBITDA guide of '$38M+' implies a staggering $15M+ hit to profitability. Can you bridge this gap? How much is purely related to adding new sales headcount versus lost operating leverage from lower procedure volumes?
Confidence in H2 Turnaround
You've modeled a return to procedure growth in H2 2026, yet the decline accelerated from -10.4% in Q3 to -13.0% in Q4. What precise leading indicators (e.g., new rep productivity, clinic onboarding times) give you confidence the bleeding stops by mid-year?
GLP-1 Market Dynamics
Is the ongoing procedure revenue weakness completely driven by internal execution missteps during the sales reorg, or are you finally beginning to see systemic pressure from alternative therapies like GLP-1s impacting patient discretionary spend?